ArticleCancer research2009
Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- UXT enhances melanoma proliferation, migration, and invasion through modulation of the P53 signaling pathway.Cell division · 2025Article
- UXT at the crossroads of cell death, immunity and neurodegenerative diseases.Frontiers in oncology · 2023Review
- UXT in Sertoli cells is required for blood-testis barrier integrity†.Biology of reproduction · 2020Article
- Article
- Prostate-specific loss of UXT promotes cancer progression.Oncotarget · 2019Article
- UXT is required for spermatogenesis in mice.PloS one · 2018Article
- Article
- BAP18 coactivates androgen receptor action and promotes prostate cancer progression.Nucleic acids research · 2016Article
- TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.Endocrine-related cancer · 2014Article
- Androgen receptor coactivators that inhibit prostate cancer growth.American journal of clinical and experimental urology · 2014Review
- Art27 interacts with GATA4, FOG2 and NKX2.5 and is a novel co-repressor of cardiac genes.PloS one · 2014Article
- Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.Oncogene · 2013Article
- Functional domains of androgen receptor coactivator p44/Mep50/WDR77and its interaction with Smad1.PloS one · 2013Article
- Analysis of URI nuclear interaction with RPB5 and components of the R2TP/prefoldin-like complex.PloS one · 2013Article
- Androgen receptor co-activators in the regulation of cellular events in prostate cancer.World journal of urology · 2012Review
- Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP.Molecular and cellular biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
The androgen receptor (AR) directs diverse biological processes through interaction with coregulators such as AR trapped clone-27 (ART-27). Our results show that ART-27 is recruited to AR-binding sites by chromatin immunoprecipitation analysis. In addition, the effect of ART-27 on genome-wide transcription was examined. The studies indicate that loss of ART-27 enhances expression of many androgen-regulated genes, suggesting that ART-27 inhibits gene expression. Surprisingly, classes of genes that are up-regulated upon ART-27 depletion include regulators of DNA damage checkpoint and cell cycle progression, suggesting that ART-27 functions to keep expression levels of these genes low. Consistent with this idea, stable reduction of ART-27 by short-hairpin RNA enhances LNCaP cell proliferation compared with control cells. The effect of ART-27 loss was also examined in response to the antiandrogen bicalutamide. Unexpectedly, cells treated with ART-27 siRNA no longer exhibited gene repression in response to bicalutamide. To examine ART-27 loss in prostate cancer progression, immunohistochemistry was conducted on a tissue array containing samples from primary tumors of individuals who were clinically followed and later shown to have either recurrent or nonrecurrent disease. Comparison of ART-27 and AR staining indicated that nuclear ART-27 expression was lost in the majority of AR-positive recurrent prostate cancers. Our studies show that reduction of ART-27 protein levels in prostate cancer may facilitate antiandrogen-resistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.